Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2008-11-25
2010-11-16
Chernyshev, Olga N (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S001100, C514S021200, C530S350000, C530S358000
Reexamination Certificate
active
07833975
ABSTRACT:
To provide a prophylactic/therapeutic agent for neurodegenerative diseases (such as polyglutamine diseases), the agent containing an HMGB family protein or a derivative thereof, such as a protein according any one of (a) and (b) below:(a) a protein having the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8; and(b) a protein having an amino acid sequence resulting from deletion, substitution, addition or insertion of one or more amino acids in the amino acid sequence of SEQ ID NO: 2, 4, 6 or 8 and having binding activity to an abnormal polyglutamine protein produced in a neurodegenerative disease.
REFERENCES:
patent: 7288250 (2007-10-01), Newman et al.
patent: 2006/0084072 (2006-04-01), Muchowski
patent: 2003-267874 (2003-09-01), None
patent: 2004/061456 (2004-07-01), None
patent: 2005/025604 (2005-03-01), None
Takata, Kazuyuki et al, Role of High Mobility Group Protein-1 (HMG1) in amyloid-β homeostasis, Biochemical and Biophysical Research Communications, 2003, vol. 301, No. 3, p. 699-703.
Agresti, Alessandra et al, HMGB Proteins and Gene Expression, Current Opinion in Genetics & Development, 2003, vol. 13, No. 2, p. 170-178.
Travers, Priming the Nucleosome: A Role for HMGB Proteins?, European Molecular Biology Organization, EMBO Reports, vol. 4, No. 2, 2003, p. 131-136.
Alpha-synuclein filaments bind the transcriptional regulator HMGB-1, Lindersson, E. et al, Neuroreport, vol. 15, No. 18, Dec. 22, 2004, pp. 2735-2739. XP008114956.
Dangerous liaisons: polyglutamine meets HMGB, Todi, S. et al., Nature Cell Biology, vol. 9, No. 4, Apr. 2007, pp. 359-361. XP002555670.
Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases, Qi, M. et al, Nature Cell Biology, vol. 9, No. 4, Apr. 2007, pp. 402-414, Supplementary Information pp. 1-7 with Supplementary Methods (3 pages). XP002555671.
Proteome analysis of soluble nuclear proteins links genotoxic stress to the polyglutamine disease pathology, Okazawa, H., Abstracts/Neuroscience Research, Elsevier, Shannon, IR, vol. 58, Jan. 1, 2007, pp. S16. XP022174779.
Polyglutamine diseases: a transcription disorder?, Okazawa, H., CMLS Cellular and Molecular Life Sciences, vol. 60, No. 7, Jul. 1, 2003, pp. 1427-1439. XP003006820.
Polyglutamine and CBP: fatal attraction?, McCampbell, A. et al., Nature Medicine, vol. 7, No. 5, May 2001, pp. 528-530. XP002555674.
Polyglutamine disease: acetyltransferases awry, Hughes, Current Biology, vol. 12, No. 4, Feb. 19, 2002, pp. R141-R143. XP009116273.
Expanded polyglutamine stretches lead to aberrant transcriptional regulation in polyglutamine diseases, Shimohata, T. et al, Human Cell, vol. 14, No. 1, Mar. 1, 2001, pp. 17-25. XP008114385.
To the 30-nm chromatin fiber and beyond, Adkins et al., Biochimica et Biophysica Acta. Gene Structure and Expression, Elsevier, Amsterdam, NL, vol. 1677, No. 1-3, Mar. 15, 2004, pp. 12-23. XP004496566.
Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin, Wang, H. et al., Human Molecular Genetics, vol. 15, No. 6, Mar. 2006, pp. 1025-1041. XP002555672.
Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity, Apostol, B. et al., Human Molecular Genetics, vol. 15, No. 2, Jan. 2006, pp. 273-285. XP002555673.
Transcriptional repression and cell death induced by nuclear aggregates of non-polyglutamine protein, Fu, L. et al, Neurobiology of Disease, vol. 20, No. 3, Dec. 1, 2005, pp. 656-665. XP005153852.
Carmody & Torrance LLP
Chernyshev Olga N
National University Corporation Tokyo Medical and Dental Univers
LandOfFree
Prophylactic/therapeutic agent for neurodegenerative disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prophylactic/therapeutic agent for neurodegenerative disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic/therapeutic agent for neurodegenerative disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4247154